Intra-Cellular Therapies (ITCI) Competitors

Intra-Cellular Therapies (NASDAQ:ITCI) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations.

Does the media refer more to ITCI or TAK?

In the previous week, Intra-Cellular Therapies had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 11 mentions for Intra-Cellular Therapies and 5 mentions for Takeda Pharmaceutical. Intra-Cellular Therapies' average media sentiment score of 1.04 beat Takeda Pharmaceutical's score of 0.74 indicating that Intra-Cellular Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intra-Cellular Therapies	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in ITCI or TAK?

Intra-Cellular Therapies received 422 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 66.50% of users gave Intra-Cellular Therapies an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Intra-Cellular Therapies	Outperform Votes 522 66.50%	Underperform Votes 263 33.50%
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%

Do insiders & institutionals have more ownership in ITCI or TAK?

92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more risk and volatility, ITCI or TAK?

Intra-Cellular Therapies has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Which has stronger earnings & valuation, ITCI or TAK?

Takeda Pharmaceutical has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intra-Cellular Therapies	$680.50M	20.58	-$139.67M	-$0.73	-180.41
Takeda Pharmaceutical	$4.58T	0.01	$994.06M	$0.40	37.54

Is ITCI or TAK more profitable?

Takeda Pharmaceutical has a net margin of 4.53% compared to Intra-Cellular Therapies' net margin of -14.07%. Takeda Pharmaceutical's return on equity of 9.39% beat Intra-Cellular Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intra-Cellular Therapies	-14.07%	-9.93%	-8.38%
Takeda Pharmaceutical	4.53%	9.39%	4.53%

Do analysts recommend ITCI or TAK?

Intra-Cellular Therapies currently has a consensus target price of $106.08, suggesting a potential downside of 19.46%. Given Intra-Cellular Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Intra-Cellular Therapies is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intra-Cellular Therapies	0 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.47
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Intra-Cellular Therapies beats Takeda Pharmaceutical on 12 of the 19 factors compared between the two stocks.